Abstract: Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, wherein X1, X2, X3, X4, R1-R4, R5a, R5b, R6a, R6b, R7a, R7b, R8a, R8b, R9-R7 and the subscripts v and w are as herein described can trap IL-1? and are expected to have utility as therapeutic agents, for example, for treating cardiovascular disease. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cardiovascular disease and inflammatory disorders and for preparing pharmaceuticals for this purpose.

Abstract: The present application provides an antenna calibration method and apparatus, and a remote radio unit. The method includes: generating a calibration sequence of a channel to be calibrated; determining, according to obtained calibration configuration information of the channel to be calibrated and an output sequence of the channel to be calibrated, a calibration response sequence of the channel to be calibrated; and calibrating the channel to be calibrated according to the calibration response sequence of the channel to be calibrated and the calibration sequence of the channel to be calibrated.

Abstract: Embodiments of the present disclosure provide an amplitude and phase calibration method and device, a storage medium, and an electronic device. The method includes: receiving a plurality of signals to be calibrated, with the plurality of signals to be calibrated being signals of one or more digital channels; routing the plurality of signals to be calibrated to a plurality of basic units, with each of the basic units configured to process one of the signals to be calibrated; and performing amplitude and phase calibration on the plurality of signals to be calibrated by the plurality of basic units.

Abstract: This application discloses a wireless communication apparatus and a signal processing method. The wireless communication apparatus includes a power amplifier and a bias circuit. The power amplifier includes a signal input port, a signal output port, a power supply port, and a bias port. The power amplifier is configured to: receive a power supply signal through the power supply port, receive a bias signal through the bias port, receive a radio frequency signal through the signal input port, and output a power amplified radio frequency signal. The bias circuit is configured to generate the bias signal. A timing feature of the bias signal is synchronized with a timing feature of a switch signal of a power amplifier, to compensate for a nonlinear change in the TDD scenario.

Abstract: Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, wherein X1, X2, X3, R1-R9, RA, RB, RD, A1, A2, and subscripts t and w are as herein described. The compounds and their pharmaceutically acceptable salts can trap IL-1? and are expected to have utility as therapeutic agents, for example, for treating cardiovascular disease and inflammatory disorders. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cardiovascular disease and inflammatory disorders and for preparing pharmaceuticals for this purpose.

Abstract: The present application provides an antenna calibration method and apparatus, and a remote radio unit. The method includes: generating a calibration sequence of a channel to be calibrated; determining, according to obtained calibration configuration information of the channel to be calibrated and an output sequence of the channel to be calibrated, a calibration response sequence of the channel to be calibrated; and calibrating the channel to be calibrated according to the calibration response sequence of the channel to be calibrated and the calibration sequence of the channel to be calibrated.

Abstract: The cryostat may include an inner vessel configured to accommodate one or more superconducting coils, an outer vessel encompassing the inner vessel, and a thermal shield configured between the outer vessel and the inner vessel. The thermal shield may include an internal cylinder having a first end and an external cylinder encompassing the internal cylinder, the external cylinder having a second end. The thermal shield may also include a seal head configured between the internal cylinder and the external cylinder, the seal head having a first edge and a second edge. The thermal shield may further include a connecting component including a plurality of connectors. Each of the plurality of connectors may be configured to connect the first end of the internal cylinder with the first edge of the seal head and/or the second end of the external cylinder with the second edge of the seal head.

Abstract: An automated integration and test system includes a host server and a plurality of working stations. The host server is configured to execute: reviewing submitted code so as to obtain a review result; compiling the submitted code so as to obtain a compiling result in response to that the review result indicates “pass”; obtaining a compiled code in response to that the compiling result indicates “success”; and actuating one or more working stations to execute an item to be tested so as to obtain a full test result.

Abstract: A method to determine disease-specific survival, disease-free interval, progression-free interval, progression-free survival or overall survival in a cancer patient based on specific mutational signatures is provided.

Abstract: A molecular marker for diagnosing primary biliary cholangitis and a method for detecting same are provided. The anti-human multimer immunoglobulin receptor antibody is adopted as the primary biliary cholangitis diagnosis molecular marker so as to prepare the diagnosis reagent; the human multimer immunoglobulin receptor antibody is remarkably increased in serum of PBC AMA-M2 subtype positive and negative patients, which indicates that in the attack of PBC, the serum anti-human multimer immunoglobulin receptor antibody specifically targets human multimer immunoglobulin receptors on small and medium bile ducts in the liver, thereby causing damage to the small and medium bile ducts.

Abstract: Embodiments of the present disclosure provide an amplitude and phase calibration method and device, a storage medium, and an electronic device. The method includes: receiving a plurality of signals to be calibrated, with the plurality of signals to be calibrated being signals of one or more digital channels; routing the plurality of signals to be calibrated to a plurality of basic units, with each of the basic units configured to process one of the signals to be calibrated; and performing amplitude and phase calibration on the plurality of signals to be calibrated by the plurality of basic units.

Abstract: The present invention provides scaffolded antigens that have demonstrated improved biochemical and immunogenic properties. The invention also provides engineered SARS-CoV-2 immunogens that contain a modified receptor-binding domain (RBD) sequence. Also provided in the invention are vaccine compositions that contain the scaffolded antigens, including the engineered RBD polypeptides that are fused to the scaffold proteins described herein. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating SARS-CoV-2 infections.

Abstract: This application discloses a wireless communication apparatus and a signal processing method. The wireless communication apparatus includes a power amplifier and a bias circuit. The power amplifier includes a signal input port, a signal output port, a power supply port, and a bias port. The power amplifier is configured to: receive a power supply signal through the power supply port, receive a bias signal through the bias port, receive a radio frequency signal through the signal input port, and output a power amplified radio frequency signal. The bias circuit is configured to generate the bias signal. A timing feature of the bias signal is synchronized with a timing feature of a switch signal of a power amplifier, to compensate for a nonlinear change in the TDD scenario.

Abstract: The invention utilizes swelling and fusion effects of graphene oxide in a solvent to implement cross-linked bonding of a graphene material itself and materials such as polymers, metal, paper, glass, carbon materials, and ceramics. The present invention not only overcomes the shortcoming in traditional adhesives of residual formaldehyde, but also has short drying time, high bonding strength and high corrosion resistance. The present invention is widely applied in the fields of aviation, aerospace, automobiles, machinery, construction, chemical, light industry, electronics, electrical appliances, and daily life, etc.

Abstract: The present invention discloses a polyimide-based composite carbon film with high thermal conductivity and a preparation method therefor. The preparation method includes: uniformly coating the surface of a polyimide-based carbon film with an aqueous graphene oxide solution, and then covering the same with another polyimide-based carbon film uniformly coated with an aqueous graphene oxide solution; repeating such operation; after the polyimide-based carbon films are dried, bonding the polyimide-based carbon films by means of graphene oxide so as to form a thick film; bonding the polyimide-based carbon films more tightly by means of further low-temperature hot pressing; and finally, obtaining a thick polyimide-based carbon film with high thermal conductivity by repairing defects by means of low-temperature heating pre-reduction and high-temperature and high-pressure thermal treatment.

Abstract: An application of honokiol and magnolol in preparation of an MCR-1 enzyme inhibitor, provides a novel medical application of the honokiol and the magnolol in the preparation of the MCR-1 enzyme inhibitor. The honokiol and the magnolol can inhibit the activity of MCR-1 enzymes and restore the bactericidal activity of polymyxin to MCR-1 Enterobacteriaceae. In vivo experiments, the honokiol and the magnolol combined with polymyxin have a good therapeutic effect on bacterial infection expressing MCR-1, especially infections caused by MCR-1 positive Enterobacteriaceae, and have wide medical applications.

Abstract: The cryostat may include an inner vessel configured to accommodate one or more superconducting coils, an outer vessel encompassing the inner vessel, and a thermal shield configured between the outer vessel and the inner vessel. The thermal shield may include an internal cylinder having a first end and an external cylinder encompassing the internal cylinder, the external cylinder having a second end. The thermal shield may also include a seal head configured between the internal cylinder and the external cylinder, the seal head having a first edge and a second edge. The thermal shield may further include a connecting component including a plurality of connectors. Each of the plurality of connectors may be configured to connect the first end of the internal cylinder with the first edge of the seal head and/or the second end of the external cylinder with the second edge of the seal head.

Abstract: The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Abstract: Cryostat systems for magnetic resonance imaging system are provided. The cryostat system may include a tank containing a cavity to accommodate a cooling medium and a superconducting coil. The system may also include a cold head assembly configured to cool the cooling medium to maintain the superconducting coil in a superconducting state. The cold head assembly may be mounted on the tank. The cold assembly may include at least a first cold head and a second cold head. The second cold head may include a taper shape with a first end surface close to the first cold head and a second end surface away from the first cold head. A diameter of the first circular end is greater than a diameter of the second circular end.